Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-54452840 · 1 trial · 1 indication
Serum concentrations of JNJ-54452840 will be used to determine pharmacokinetic parameters for JNJ-54452840
| Arm | Type | Description |
|---|---|---|
| Group A: JNJ-54452840 20 mg | EXPERIMENTAL | Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose. |
| Group A: JNJ-54452840 80 mg | EXPERIMENTAL | Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose. |
| Group A: JNJ-54452840 240 mg | EXPERIMENTAL | Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose. |
| Group A: Placebo | PLACEBO_COMPARATOR | Each participant will receive matching placebo as a single intravenous dose. |
| Group B: JNJ-54452840 20 mg | EXPERIMENTAL | Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose. |
| Group B: JNJ-54452840 80 mg | EXPERIMENTAL | Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose. |
| Group B: JNJ-54452840 240 mg | EXPERIMENTAL | Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose. |
| Group B: Placebo | PLACEBO_COMPARATOR | Each participant will receive matching placebo as a single intravenous dose. |
| Name | Type | Description |
|---|---|---|
| JNJ-54452840 | DRUG | Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg |
| Placebo | OTHER | Single matching intravenous dose |
Inclusion Criteria: * Must be a healthy male with no clinically relevant abnormalities as determined by medical history, physical examination, blood chemistry assessments, hematologic assessments - Must be Japanese or Caucasian * Japanese participants must have been born in Japan, have resided outs...
JNJ-54452840 is an investigational small molecule developed by Johnson & Johnson. It has been studied in a Phase 1 clinical trial in healthy volunteers rather than in patients with a specific disease. No therapeutic indication for the compound has been disclosed.
JNJ-54452840 is made by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 study of the compound conducted in the United States.
JNJ-54452840 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The compound is investigational and has not been approved by the FDA for any use.
JNJ-54452840 has been evaluated in one completed Phase 1 trial, NCT01809353, titled "To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants." The study enrolled 32 healthy male volunteers in the United States.
The Phase 1 trial NCT01809353 was a randomized, double-blind, placebo-controlled study of single doses of JNJ-54452840. It enrolled 32 healthy male participants aged 20 years and older in the United States and assessed pharmacokinetics and safety in Japanese and Caucasian volunteers. The trial is completed.